GS-9973: Additional Phase II data

Data from 41 evaluable chronic lymphocytic leukemia (CLL) patients who received twice-daily 800 mg oral GS-9973 for a median of 32 weeks in the single-arm, open-label, U.S. Phase II Study 102 showed that

Read the full 338 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE